TPST vs. CDTX, IFRX, LXEO, STRO, SLN, ZNTL, ADAP, NKTX, BTAI, and FATE
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Cidara Therapeutics (CDTX), InflaRx (IFRX), Lexeo Therapeutics (LXEO), Sutro Biopharma (STRO), Silence Therapeutics (SLN), Zentalis Pharmaceuticals (ZNTL), Adaptimmune Therapeutics (ADAP), Nkarta (NKTX), BioXcel Therapeutics (BTAI), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.
Tempest Therapeutics vs.
Tempest Therapeutics (NASDAQ:TPST) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Tempest Therapeutics has a beta of -1.69, meaning that its share price is 269% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Tempest Therapeutics presently has a consensus price target of $21.67, suggesting a potential upside of 2,209.88%. Cidara Therapeutics has a consensus price target of $32.20, suggesting a potential upside of 33.06%. Given Tempest Therapeutics' higher possible upside, equities research analysts plainly believe Tempest Therapeutics is more favorable than Cidara Therapeutics.
Tempest Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -69.64% beat Tempest Therapeutics' return on equity.
In the previous week, Cidara Therapeutics had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Cidara Therapeutics and 2 mentions for Tempest Therapeutics. Cidara Therapeutics' average media sentiment score of 0.65 beat Tempest Therapeutics' score of 0.40 indicating that Cidara Therapeutics is being referred to more favorably in the news media.
Cidara Therapeutics received 351 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 70.36% of users gave Cidara Therapeutics an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote.
Cidara Therapeutics has higher revenue and earnings than Tempest Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cidara Therapeutics beats Tempest Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Tempest Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TPST) was last updated on 2/18/2025 by MarketBeat.com Staff